Found: 12
Select item for more details and to access through your institution.
Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.
- Published in:
- Oncogene, 2007, v. 26, n. 35, p. 5046, doi. 10.1038/sj.onc.1210318
- By:
- Publication type:
- Article
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.
- Published in:
- 2015
- By:
- Publication type:
- letter
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
- Published in:
- Leukemia (08876924), 2013, v. 27, n. 9, p. 1949, doi. 10.1038/leu.2013.190
- By:
- Publication type:
- Article
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
- Published in:
- Leukemia (08876924), 2009, v. 23, n. 11, p. 2007, doi. 10.1038/leu.2009.140
- By:
- Publication type:
- Article
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
- Published in:
- Leukemia (08876924), 2004, v. 18, n. 6, p. 1093, doi. 10.1038/sj.leu.2403354
- By:
- Publication type:
- Article
Macrophage migration inhibitory factor enzymatic activity, lung inflammation, and cystic fibrosis.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.
- Published in:
- 2011
- By:
- Publication type:
- journal article
MIF loss impairs Myc-induced lymphomagenesis.
- Published in:
- Cell Death & Differentiation, 2005, v. 12, n. 10, p. 1319, doi. 10.1038/sj.cdd.4401653
- By:
- Publication type:
- Article
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL).
- Published in:
- Hematological Oncology, 2017, v. 35, p. 146, doi. 10.1002/hon.2437_136
- By:
- Publication type:
- Article
PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 38, doi. 10.1002/hon.2437_20
- By:
- Publication type:
- Article
PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 131, doi. 10.1002/hon.2437_121
- By:
- Publication type:
- Article
END OF TREATMENT PET-CT PREDICTS PROGRESSION-FREE SURVIVAL IN DLBCL AFTER FIRST-LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 184, doi. 10.1002/hon.2438_45
- By:
- Publication type:
- Article